New combo therapy shows promise for rare blood cancer in younger patients
NCT ID NCT02858804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two chemotherapy regimens (EDOCH and DHAP) given one after the other, with or without the targeted drug rituximab, in 55 younger adults (65 or under) newly diagnosed with mantle cell lymphoma. The goal was to see which combination better controls the cancer and whether maintenance therapy with rituximab and other drugs helps keep the disease from returning. The trial has been completed, and results focus on how long patients live without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shuhua Yi
Tianjin, 300020, China